Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | DHFR | P00374 | 7/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | APAF1 | O14727 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | UBE2N | P61088 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361482 | 1.00 | POLB (0.63) | POLBLMNAGLAGAASMARCA2 | |
| SCHEMBL3265628 | 0.83 | POLB (0.61) | POLBLMNAGLAGAASMARCA2 | |
| SCHEMBL611438 | 0.81 | POLB (0.59) | POLBLMNAGLAGAASMARCA2 | |
| SCHEMBL29288508 | 0.81 | POLB (0.59) | POLBLMNAGLAGAASMARCA2 | |
| SCHEMBL11404500 | 0.81 | POLB (0.59) | POLBLMNAGLAGAASMARCA2 | |
| SCHEMBL29642054 | 0.81 | POLB (0.59) | POLBLMNAGLAGAASMARCA2 | |
| SCHEMBL19891460 | 0.81 | ACHE (0.49) | POLBLMNAGLAGAASMARCA2 | |
| Hydrochloric Acid SCHEMBL5251194 | 0.80 | POLB (0.62) | POLBLMNAGLAGAASMARCA2 | |
| SCHEMBL12775191 | 0.79 | POLB (0.56) | POLBLMNAGLAGAASMARCA2 | |
| SCHEMBL13901840 | 0.79 | TP53 (0.63) | POLBLMNAGLAGAASMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372311-A1 | COMPOSITIONS AND METHODS OF TREATING AGE-RELATED RETINAL DYSFUNCTION | UNIV CALIFORNIA (US) | 2023-11-23 | — | — | US | disclosed |
| US-20160201063-A1 | EPIGENETIC REGULATORS OF FRATAXIN | RANA THERAPEUTICS, INC. (US) | 2016-07-14 | — | — | US | disclosed |
| EP-3033423-A1 | EPIGENETIC REGULATORS OF FRATAXIN | Rana Therapeutics Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015023938-A1 | EPIGENETIC REGULATORS OF FRATAXIN | RANA THERAPEUTICS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| EP-2433636-A1 | Treatment of Malignant Diseases | Medizinische Universität Wien (AT) | 2012-03-28 | — | — | EP | disclosed |
| US-7091200-B2 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX U.S.A. LLC (US) | 2006-08-15 | — | — | US | disclosed |
| US-6900220-B2 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2005-05-31 | — | — | US | disclosed |
| US-20050107365-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | BECKER CYRUS K (US) | 2005-05-19 | — | — | US | disclosed |
| EP-1363899-B1 | QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-05-11 | — | — | EP | disclosed |
| EP-1363899-A1 | QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-11-26 | — | — | EP | disclosed |
| US-20030069230-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-04-10 | — | — | US | disclosed |
| WO-2002053558-A1 | QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS | F.HOFFMAN-LA ROCHE AG (CH) | 2002-07-11 | — | — | WO | disclosed |
| EP-0060081-B1 | PIPERAZINOQUINAZOLINE ANTIHYPERTENSIVES, PROCESSES FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND IMMUNOGENIC PROTEIN CONJUGATES FORMED FROM THEM | PFIZER INC. (US) | 1985-07-17 | — | — | EP | disclosed |
| EP-0028473-B1 | CHLORO- AND ALKOXY-SUBSTITUTED-2,4-DIAMINOQUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER INC. (US) | 1985-01-09 | — | — | EP | disclosed |
| US-4377581-A | ANTIHYPERTENSIVE AGENTS | PFIZER INC. (US) | 1983-03-22 | — | — | US | disclosed |
| US-4351940-A | Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines | PFIZER INC. (US) | 1982-09-28 | — | — | US | disclosed |
| EP-0060081-A2 | Piperazinoquinazoline antihypertensives, processes for preparing them, pharmaceutical compositions containing them, and immunogenic protein conjugates formed from them | PFIZER INC. (US) | 1982-09-15 | — | — | EP | disclosed |
| US-4287341-A | USEFUL AS ANTIHYPERTENSIVE AGENTS | PFIZER INC. (US) | 1981-09-01 | — | — | US | disclosed |
| EP-0028473-A1 | Chloro- and alkoxy-substituted-2,4-diaminoquinazolines and pharmaceutical compositions containing them | PFIZER INC. (US) | 1981-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069230-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRB2, ADRA2B | POLB 1579/4885LMNA 1587/4885GLA 2427/4885 |
| US-20230372311-A1 | COMPOSITIONS AND METHODS OF TREATING AGE-RELATED RETINAL DYSFUNCTION | RBP4, ALDH1A2, RBP1 | POLB 617/4885LMNA 147/4885GLA 83/4885 |
| US-20050107365-A1 | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRB2, ADRA2B | POLB 1594/4885LMNA 1493/4885GLA 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.